Humans ; Hypertension, Portal ; diagnosis ; etiology ; therapy ; Pancreatic Diseases ; complications

Child ; Child, Preschool ; Female ; Humans ; Hypertension, Portal ; diagnosis ; etiology ; therapy ; Infant ; Male ; Portal Vein ; pathology ; Venous Thrombosis ; diagnosis ; etiology ; therapy

Esophageal and Gastric Varices ; etiology ; therapy ; Hemodynamics ; Humans ; Hypertension, Portal ; complications ; therapy ; Liver Cirrhosis ; complications ; therapy ; Portal Vein ; physiopathology

Esophageal and Gastric Varices ; etiology ; surgery ; Gastrointestinal Hemorrhage ; etiology ; therapy ; Hemostasis, Endoscopic ; Humans ; Hypertension, Portal ; complications

Humans ; Hypertension, Portal ; etiology ; therapy ; Liver Cirrhosis ; complications ; therapy ; Portasystemic Shunt, Transjugular Intrahepatic

This report describes a case of portal hypertension caused by periportal tuberculous lymphadenitis. There were a few reports of portal hypertension associated with tuberculosis. A 27-year-old man was admitted to the hospital because of recurrent hematemesis for 7 days. There was a history of mediastinal tuberculous lymphadenitis 3 years earlier that was treated with isoniazide, rifampin, ethambutol, and pyrazinamide for 2 years. Clinical evaluation revealed esophageal variceal bleeding and main portal vein obstruction by enlarged periportal lymph nodes. The patient underwent distal splenorenal shunt. Pathologic examination of the excised periportal lymph node revealed chronic granulomatous inflammation with central caseous necrosis. Thereafter the patient took antituberculous medication for 12 months. The patient has not re-bled 3 years since the shunt operation.
Adult ; Case Report ; Human ; Hypertension, Portal/*etiology/therapy ; Male ; Tuberculosis, Lymph Node/*complications

Ascites ; etiology ; therapy ; Diuretics ; therapeutic use ; Humans ; Hypertension, Portal ; complications ; Peritoneovenous Shunt ; Portasystemic Shunt, Transjugular Intrahepatic

Gastrointestinal Hemorrhage ; drug therapy ; etiology ; prevention & control ; Humans ; Hypertension, Portal ; complications

OBJECTIVESTo observe the effects and safety of percutaneous transhepatic coronary vein occlusion under ultrasound type B and X-ray guiding to treat esophagogastric variceal hemorrhage in cirrhotic patients.

METHODSEighteen cirrhotic patients suffering from esophagogastric variceal hemorrhage were treated with percutaneous transhepatic coronary vein occlusion under ultrasound type B and X-ray guiding. Among them, 8 patients were treated during emergency bleeding and another 10 patients after hemorrhage.

RESULTSSeventeen patients were successfully treated with coronary vein occlusion. One patient rebled after 6 hours of the treatment and was treated successfully with transjugular intrahepatic portosystemic shunt. The emergency hemostatic treatment efficacy was 87.5%, and successful occlusion occurred in 94.4%. All patients were followed up for 1 to 24 months. There were 4 patients who suffered from rebleeding, 2 patients from hepatic failure and 2 patients from hepatocellular carcinoma. There were 12 patients survived during the follow-up.

CONCLUSIONPercutaneous transhepatic coronary vein occlusion under the type B ultrasonography and X-ray guiding is safe and efficient to treat esophagogastric variceal hemorrhage in cirrhotic patients

Esophageal and Gastric Varices ; etiology ; Female ; Gastrointestinal Hemorrhage ; etiology ; therapy ; Hemorrhage ; therapy ; Humans ; Hypertension, Portal ; complications ; Liver Cirrhosis ; complications ; Male ; Middle Aged ; Portal Vein

Endoscopy, Digestive System ; Esophageal and Gastric Varices ; complications ; drug therapy ; surgery ; therapy ; Fibrosis ; complications ; Gastrointestinal Hemorrhage ; drug therapy ; etiology ; surgery ; therapy ; Humans ; Hypertension, Portal ; drug therapy ; etiology ; surgery ; therapy